Coronavirus is afraid of statins: people taking them have 25% lower risk of death

Coronavirus mortality declines in statin use

Currently, the coronavirus infected almost 40 million people on our planet. Over one million patients died in less than a year. But it is still not clear why some people show symptoms when infected, while others do not. In some cases, doctors learned to predict the diagnosis based on age, existing diseases, but they cannot say with certainty how the coronavirus will develop in each individual case.

The statins are considered as one of the treatment methods today. The drug helps to lower blood cholesterol levels, it prevents cardiovascular diseases. Now the statins are taken by one in four people, and it is one of the most common drugs on the planet.

The researchers studied the effects of the statins and concluded that people who receive treatment have a 20-255% lower risk of dying from the COVID-19. During the study, the conditions of almost 2.1 thousand patients from 19 hospitals in Catalonia were studied.

They were treated during the first wave of the epidemic. The doctors estimated one hundred clinical variables for each patient, taking gender, age, previous illnesses, the evolution of the virus, and methods of treating the coronavirus into account.

The researchers then compared the mortality rates of those patients who took statins and those who did not. The percentage of patients who died in the statin-free group was 25.4. And the percentage among those who were treated with the statins was 22% lower.

According to the researchers, these data point to the fact that statin treatment can prevent one in five deaths. In addition, the use of these drugs was found to be important during the hospitalization. In that case, mortality is reduced by 25%.

As a result, the studies demonstrate the fact that statins not only do not have a negative effect on the body, but also reduce the mortality rate.

Masana, L., et al. (2020) Effect of statin therapy on Sars-CoV-2 infection-related mortality in hospitalized patients. European Heart Journal - Cardiovascular Pharmacotherapy.